在患有IgA脏病的患者中进行阿塔西塞普的第三阶段试验
Richard Lafayette1, Sean J Barbour2, Robert M Brenner3
1Stanford University, Stanford, CA.
The New England journal of medicine
|November 6, 2025
概括
在IgA脏病患者中,阿塔西cept显著降低了蛋白尿症. 这种IgA脏病治疗显示,蛋白质与肌素的比率减少了45.7%,而安慰剂治疗为6.8%.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
背景情况:
- IgA脏病是导致功能衰竭的主要原因,由免疫复合物的沉积驱动.
- 目前的治疗方法有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 评估阿塔西塞普特在IgA脏病患者的疗效和安全性.
- 评估阿塔西对蛋白尿的影响,蛋白尿是病进展的关键标志物.
主要方法:
- 一个3期,随机,双盲,安慰剂对照试验,涉及203名IgA脏病患者.
- 患者每周接受150毫克皮下注射阿塔西塞普或与之匹配的安慰剂.
- 主要终点是36周后24小时尿蛋白与肌素比率的变化.
主要成果:
- 在36周后,阿塔西cept显示蛋白尿症减少了45.7%,而安慰剂组的减少率为6.8%.
- 这代表了41.8个百分点的显著差异 (P<0.001).
- 不良事件在两组之间是可比的,大多是轻度至中度的.
结论:
- 在IgA脏病患者中,阿塔西cept显著降低蛋白尿症.
- 这表明阿塔西塞普是IgA脏病的有前途的治疗选择.
- 需要进一步的研究和长期数据.
相关概念视频
Acute Kidney Injury III: Clinical Manifestations
791
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
791
Acute Kidney Injury IV: Diagnostic Studies and Prevention
254
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
254
Chronic Kidney Disease III: Interprofessional Care
331
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
331
Nephrotic Syndrome III : Nursing Management
272
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
272
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307


